Solexa, Inc. Reports Third Quarter Financial Results; Technology Platform Demonstrates Success In Resequencing Human DNA

HAYWARD, Calif. & CAMBRIDGE, U.K.--(BUSINESS WIRE)--Nov. 14, 2005--Solexa, Inc. (Nasdaq: SLXA) today announced financial results for the third quarter and nine months ended September 30, 2005. "We have made substantial strides in preparing for the launch of our next-generation genetic analysis instrument system, which we are developing to dramatically reduce the cost and increase the speed of DNA sequencing," said John West, chief executive officer of Solexa. "Among these, we have completed a major initiative to strengthen our leadership by adding key executive and scientific professionals. Further, last month we announced the successful resequencing of a human bacterial artificial chromosome, which demonstrates that our reversible-terminator chemistry and Clonal Single-Molecule Array(TM) technology can be applied to resequence human DNA.

Back to news